With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
News|Articles|July 15, 2010
Dietary supplements: Beware of fake remedies
The Dietary Supplement Health and Education Act of 1994 greatly reduced FDA involvement in assessing the safety of dietary supplements, leaving pharmacists with the problem of obtaining accurate information with which to advise patients.
Advertisement
Key Points
Advertisement
Related to this article
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.
Investigators link oversight with eroding trust in health authorities and call on future pandemic inquiries to weigh trade-offs.
Lara Zakaria, PharmD, MS, CNS, FMCP, illustrates the breadth of health technology going in and out of community pharmacy practice.
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
2
Trutakna Reduces Proteinuria in Adults With Primary IgAN
3
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
4
Harms of Public Health Measures Overlooked in COVID-19 Policy Reviews
5